Dissecting resistance to endocrine therapy in breast cancer

Cell Cycle

Volumn 7, Issue 13, 2008, Pages 1895-1898

  Lord, Christopher J ^a   Iorns, Elizabeth ^a   Ashworth, Alan ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

CDK10; Endocrine therapy; Resistance; RNA interference; SiRNA screen; Tamoxifen

Indexed keywords

4 HYDROXYTAMOXIFEN; 5 (4 BROMO 2 CHLOROANILINO) 4 FLUORO 1 METHYL 1H BENZIMIDAZOLE 6 CARBOHYDROXAMIC ACID 2 HYDROXYETHYL ESTER; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 10; ESTROGEN RECEPTOR ALPHA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; SMALL INTERFERING RNA; SORAFENIB; TAMOXIFEN; TAMOXIFEN CITRATE;

ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER RESISTANCE; CDK10 GENE; CELL CYCLE REGULATION; DNA LIBRARY; GENE; HUMAN; NONHUMAN; RNA INTERFERENCE;

EID: 47749155641     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.7.13.6118     Document Type: Article

References (32)

1. Beatson G. On the treatment of inoperable cases of carcinoma of the mammary. Suggestions for a new method of treatment with illustrative cases. Lancet 1896; 2:104-7.
2. EBCTCG. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998; 351:1451-67.
3. Frasor J, Danes JM, Komm B, Chang KC, Lyttle CR, Katzenellenbogen BS. Profiling of estrogen up and downregulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell pheno-type. Endocrinology 2003; 144:4562-74.
4. Jenuwein T, Allis CD. Translating the histone code. Science 2001; 293:1074-80.
5. Sabbah M, Courilleau D, Mester J, Redeuilh G. Estrogen induction of the cyclin D1 promoter: involvement of a cAMP response-like element. Proceedings of the National Academy of Sciences of the United States of America 1999; 96:11217-22.
6. Buckley M F, Sweeney KJ, Hamilton JA, Sini RL, Manning DL, Nicholson RI, deFazio A, Watts CK, Musgrove EA, Sutherland RL. Expression and amplification of cyclin genes in human breast cancer. Oncogene 1993; 8:2127-33.
7. Dubik D, Shiu R P. Transcriptional regulation of c-myc oncogene expression by estrogen in hormone-responsive human breast cancer cells. The Journal of biological chemistry 1988; 263:12705-8.
8. Lathrop AE, Loeb L. Further investigations on the origin of tumors in mice. III. On the part played by internal secretion in the spontaneous development of tumors. J Cancer Res 1916; 1:1-19.
9. Allen E, Doisy EA. Landmark article Sept 8, 1923. An ovarian hormone. Preliminary report on its localization, extraction and partial purification, and action in test animals. By Edgar Allen and Edward A. Doisy. Jama 1983; 250:2681-3.
10. Jensen E V, Block GE, Smith S, Kyser K, DeSombre ER. Estrogen receptors and breast cancer response to adrenalectomy. Natl Cancer Inst Monogr 1971; 34:55-70.
11. McGuire WL. Quantitation of estrogen receptor in mammary carcinoma. Methods in enzymology 1975; 36:248-54.
12. Osborne CK. Tamoxifen in the treatment of breast cancer. The New England journal of medicine 1998; 339:1609-18.
13. Ring A, Dowsett M. Mechanisms of tamoxifen resistance. Endocr Relat Cancer 2004; 11:643-58.
14. Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. Journal of the National Cancer Institute 2004; 96:926-35.
15. Oh AS, Lorant LA, Holloway JN, Miller DL, Kern FG, El-Ashry D. Hyperactivation of MAPK induces loss of ERalpha expression in breast cancer cells. Mol Endocrinol 2001; 15:1344-59.
16. Wilcken NR, Prall OW, Musgrove EA, Sutherland RL. Inducible overexpression of cyclin D1 in breast cancer cells reverses the growth-inhibitory effects of antiestrogens. Clin Cancer Res 1997; 3:849-54.
17. Nicholson RI, Hutcheson IR, Knowlden JM, Jones HE, Harper ME, Jordan N, Hiscox SE, Barrow D, Gee JM. Nonendocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combination. Clin Cancer Res 2004; 10:346-54.
18. Dorssers LC, Van der Flier S, Brinkman A, van Agthoven T, Veldscholte J, Berns EM, Klijn JG, Beex LV, Foekens JA. Tamoxifen resistance in breast cancer: elucidating mechanisms. Drugs 2001; 61:1721-33.
19. Iorns E, Lord CJ, Turner N, Ashworth A. Utilizing RNA interference to enhance cancer drug discovery. Nat Rev Drug Discov 2007; 6:556-68.
20. Iorns E, Turner NC, Elliott R, Syed N, Garrone O, Gasco M, Tutt AN, Crook T, Lord CJ, Ashworth A. Identification of CDK10 as an Important Determinant of Resistance to Endocrine Therapy for Breast Cancer. Cancer cell 2008; 13:91-104.
21. Napoli C, Lemieux C, Jorgensen R. Introduction of a chimeric chalcone synthase gene into petunia results in reversible co-suppression of homologous genes in trans. Plant Cell 1990; 2:279-89.
22. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391:806-11.
23. Abdi H. Z-Scores. In: Salkind N, ed. Encyclopedia of Measurement and Statistics. Thousand Oaks (CA): Sage 2007; 1-4.
24. Gee JM, Robertson J F, Ellis IO, Nicholson RI. Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. International journal of cancer 2001; 95:247-54.
25. Hopkins AL, Groom CR. The druggable genome. Nat Rev Drug Discov 2002; 1:727-30.
26. Lavoie JN, L'Allemain G, Brunet A, Muller R, Pouyssegur J. Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway. The Journal of biological chemistry 1996; 271:20608-16.
27. Kasten M, Giordano A. Cdk10, a Cdc2-related kinase, associates with the Ets2 transcription factor and modulates its transactivation activity. Oncogene 2001; 20:1832-8.
28. Swanton C, Downward J. Unraveling the complexity of endocrine resistance in breast cancer by functional genomics. Cancer cell 2008; 13:83-5.
29. INK4a messenger RNA is a marker of poor prognosis. Clin Cancer Res 2000; 6:2777-87.
30. Thompson N, Lyons J. Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery. Current opinion in pharmacology 2005; 5:350-6.
31. Gazin C, Wajapeyee N, Gobeil S, Virbasius CM, Green MR. An elaborate pathway required for Ras-mediated epigenetic silencing. Nature 2007; 449:1073-7.
32. Morris SR, Carey LA. Gene expression profiling in breast cancer. Curr Opin Oncol 2007; 19:547-51.